NASDAQ:IMGNImmunoGen Stock Price, Forecast & News

ImmunoGen's stock was trading at $3.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IMGN stock has increased by 44.2% and is now trading at $4.86. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ImmunoGen.

ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for ImmunoGen.

ImmunoGen, Inc. (NASDAQ:IMGN) posted its earnings results on Friday, May, 1st. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.02. The biotechnology company earned $13.29 million during the quarter, compared to analysts' expectations of $14.53 million. View ImmunoGen's earnings history.

ImmunoGen issued an update on its FY 2020 Pre-Market earnings guidance on Friday, May, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $60-65 million, compared to the consensus revenue estimate of $62.72 million.

4 Wall Street analysts have issued 12 month target prices for ImmunoGen's shares. Their forecasts range from $9.00 to $12.00. On average, they anticipate ImmunoGen's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 116.0% from the stock's current price. View analysts' price targets for ImmunoGen.

News articles about IMGN stock have been trending somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. ImmunoGen earned a news impact score of -1.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutImmunoGen.

Some companies that are related to ImmunoGen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Immunomedics (IMMU), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), NVIDIA (NVDA), Opko Health (OPK), Amarin (AMRN) and Exelixis (EXEL).

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (10.98%), Redmile Group LLC (9.59%), BlackRock Inc. (7.81%), Clearbridge Investments LLC (4.76%), State Street Corp (3.28%) and RA Capital Management L.P. (2.96%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Craig Barrows, David Brannon Johnston, David G Foster, Mark Alan Goldberg, Mark J Enyedy, Richard J Gregory and Thomas Ryll. View institutional ownership trends for ImmunoGen.

IMGN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Primecap Management Co. CA, Clearbridge Investments LLC, Invesco Ltd., JPMorgan Chase & Co., Squarepoint Ops LLC, and Raymond James & Associates. Company insiders that have sold ImmunoGen company stock in the last year include Craig Barrows, David G Foster, Mark J Enyedy, and Thomas Ryll. View insider buying and selling activity for ImmunoGen.

IMGN stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, RA Capital Management L.P., Redmile Group LLC, BlackRock Inc., Deutsche Bank AG, Nuveen Asset Management LLC, Healthcare of Ontario Pension Plan Trust Fund, and State Street Corp. View insider buying and selling activity for ImmunoGen.

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IMGN stock can currently be purchased for approximately $4.86.

ImmunoGen has a market capitalization of $847.61 million and generates $82.27 million in revenue each year. The biotechnology company earns $-104,130,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. ImmunoGen employs 296 workers across the globe.

The official website for ImmunoGen is www.immunogen.com.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]